Chai Discovery Headlines

Pharmacy Times

An analysis of the Chai Discovery-Eli Lilly collaboration, highlighting the role of AI in biologics discovery and the potential impact.

Companies:Chai Discovery

HealthCare Middle East & Africa

Pfizer enters licensing agreement with Chai Discovery to accelerate drug discovery using AI, gaining early access to Chai-3.

Companies:Chai Discovery

Pharmaceutical Technology

Pfizer signs a licensing agreement with Chai Discovery to integrate its AI platform into drug discovery operations, gaining access to Chai-3 model.

Companies:Chai Discovery

Pharmaceutical Tech

Chai Discovery enters a licensing agreement with Pfizer to integrate its AI platform into Pfizer's drug discovery operations.

Companies:Chai Discovery

American Pharmaceutical Review

Pfizer licenses Chai Discovery's AI platform for drug research, including access to Chai-3 and a custom model.

Companies:Chai Discovery

BioSpace

Chai Discovery announces a licensing agreement with Pfizer, giving Pfizer early access to Chai-3 and a custom model.

Companies:Chai Discovery

Pharma Journalist

Chai Discovery enters a licensing agreement with Pfizer, giving Pfizer access to its AI platform and Chai-3 model.

Companies:Chai Discovery

Yahoo Finance

Pfizer has licensed Chai Discovery's AI drug discovery platform, gaining access to the Chai-3 model and a custom model trained on Pfizer's data.

Companies:Chai Discovery

Yahoo Finance

Chai Discovery announces a licensing agreement with Pfizer, providing early access to Chai-3 and a custom model.

Companies:Chai Discovery

MarketMinute

Chai Discovery announces a license agreement with Pfizer to use its AI platform, including the Chai-3 model, to accelerate drug discovery.

Companies:Chai Discovery

Forbes

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.

Companies:Chai Discovery

TechFastForward

The article reports on record AI drug discovery funding in Q1 2026, including Chai Discovery's $130M Series B with OpenAI participation.

Companies:Chai Discovery

theaiinsider.tech

The article lists 20 enterprise AI drug discovery CEOs, including Chai Discovery's Josh Meier, and highlights the company's $130M Series B, $1.3B valuation, and focus on AI-driven molecular design.

Companies:Chai Discovery

IntuitionLabs

In-depth analysis of Chai Discovery's partnership with Eli Lilly for AI biologics design.

Companies:Chai Discovery

GEN (Genetic Engineering & Biotechnology News)

Eli Lilly announced collaborations with several partners, including Chai Discovery, to expand its AI footprint in drug discovery.

Companies:Chai Discovery

Yahoo Finance

A new Pulse Report from BCC Research highlights how AI is transforming neuroprotective therapies. Chai Discovery is listed among companies that recently raised significant venture capital, with $70 million.

Companies:Chai Discovery

AI World Journal

Chai Discovery is highlighted as a notable example of AI-driven biotechnology, developing advanced AI models to predict and reprogram interactions between biochemical molecules. Their generative AI platform designs antibodies and therapeutic molecules, accelerating drug discovery. The company is backed by major investors including OpenAI and leading venture capital firms, treating biology as an information system and drug discovery as a computational engineering challenge.

Companies:Chai Discovery

GEN - Genetic Engineering and Biotechnology News

Chai Discovery, an AI-driven biologics company, is developing therapeutics against undruggable targets using its Chai-2 model for de novo antibody design. They recently announced a collaboration with Eli Lilly to deploy Chai's technology for designing novel biologics and developing an exclusive AI model tailored to Lilly's discovery workflows. This partnership aims to accelerate drug discovery by reducing reliance on labor-intensive experimental screens.

Companies:Chai Discovery

Chai Discovery

This article from Chai Discovery announces our $70M Series A fundraise. It provides details about this new development.

Companies:Chai Discovery

Bloomberg

OpenAI and Thrive Capital have invested in a six-month-old AI drug-discovery startup. This funding round supports the nascent company's efforts to leverage artificial intelligence in the development of new drugs. The article from Bloomberg reports on this significant backing for the young startup.

Companies:Chai Discovery